Cargando…

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes

OBJECTIVE: This randomized controlled trial aimed to compare the efficacy and safety of insulin detemir (IDet) with neutral protamine Hagedorn (NPH), both with insulin aspart, in pregnant women with type 1 diabetes. The perinatal and obstetric pregnancy outcomes are presented. METHODS: Subjects were...

Descripción completa

Detalles Bibliográficos
Autores principales: Hod, Moshe, Mathiesen, Elisabeth R, Jovanovič, Lois, McCance, David R, Ivanisevic, Marina, Durán-Garcia, Santiago, Brøndsted, Lise, Nazeri, Avideh, Damm, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa UK Ltd. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862070/
https://www.ncbi.nlm.nih.gov/pubmed/23617228
http://dx.doi.org/10.3109/14767058.2013.799650
_version_ 1782295714182725632
author Hod, Moshe
Mathiesen, Elisabeth R
Jovanovič, Lois
McCance, David R
Ivanisevic, Marina
Durán-Garcia, Santiago
Brøndsted, Lise
Nazeri, Avideh
Damm, Peter
author_facet Hod, Moshe
Mathiesen, Elisabeth R
Jovanovič, Lois
McCance, David R
Ivanisevic, Marina
Durán-Garcia, Santiago
Brøndsted, Lise
Nazeri, Avideh
Damm, Peter
author_sort Hod, Moshe
collection PubMed
description OBJECTIVE: This randomized controlled trial aimed to compare the efficacy and safety of insulin detemir (IDet) with neutral protamine Hagedorn (NPH), both with insulin aspart, in pregnant women with type 1 diabetes. The perinatal and obstetric pregnancy outcomes are presented. METHODS: Subjects were randomized to IDet (n = 152) or NPH (n = 158) ≤12 months before pregnancy or at 8–12 gestational weeks. RESULTS: For IDet and NPH, there were 128 and 136 live births, 11 and 9 early fetal losses, and two and one perinatal deaths, respectively. Gestational age at delivery was greater for children from the IDet arm than the NPH arm (treatment difference: 0.49 weeks [95% CI 0.11;0.88], p = 0.012, linear regression). Sixteen children had a malformation (IDet: n = 8/142, 5.6%; NPH: n = 8/145, 5.5%). The incidence of adverse events was similar between treatments. CONCLUSION: IDet is as well tolerated as NPH as regards perinatal outcomes in pregnant women with type 1 diabetes and no safety issues were identified.
format Online
Article
Text
id pubmed-3862070
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Informa UK Ltd.
record_format MEDLINE/PubMed
spelling pubmed-38620702013-12-16 A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes Hod, Moshe Mathiesen, Elisabeth R Jovanovič, Lois McCance, David R Ivanisevic, Marina Durán-Garcia, Santiago Brøndsted, Lise Nazeri, Avideh Damm, Peter J Matern Fetal Neonatal Med Original Article OBJECTIVE: This randomized controlled trial aimed to compare the efficacy and safety of insulin detemir (IDet) with neutral protamine Hagedorn (NPH), both with insulin aspart, in pregnant women with type 1 diabetes. The perinatal and obstetric pregnancy outcomes are presented. METHODS: Subjects were randomized to IDet (n = 152) or NPH (n = 158) ≤12 months before pregnancy or at 8–12 gestational weeks. RESULTS: For IDet and NPH, there were 128 and 136 live births, 11 and 9 early fetal losses, and two and one perinatal deaths, respectively. Gestational age at delivery was greater for children from the IDet arm than the NPH arm (treatment difference: 0.49 weeks [95% CI 0.11;0.88], p = 0.012, linear regression). Sixteen children had a malformation (IDet: n = 8/142, 5.6%; NPH: n = 8/145, 5.5%). The incidence of adverse events was similar between treatments. CONCLUSION: IDet is as well tolerated as NPH as regards perinatal outcomes in pregnant women with type 1 diabetes and no safety issues were identified. Informa UK Ltd. 2014-01 2013-06-04 /pmc/articles/PMC3862070/ /pubmed/23617228 http://dx.doi.org/10.3109/14767058.2013.799650 Text en © 2014 Informa UK Ltd. All rights reserved: reproduction in whole or part not permitted http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited.
spellingShingle Original Article
Hod, Moshe
Mathiesen, Elisabeth R
Jovanovič, Lois
McCance, David R
Ivanisevic, Marina
Durán-Garcia, Santiago
Brøndsted, Lise
Nazeri, Avideh
Damm, Peter
A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
title A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
title_full A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
title_fullStr A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
title_full_unstemmed A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
title_short A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
title_sort randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine hagedorn in type 1 diabetes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862070/
https://www.ncbi.nlm.nih.gov/pubmed/23617228
http://dx.doi.org/10.3109/14767058.2013.799650
work_keys_str_mv AT hodmoshe arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT mathiesenelisabethr arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT jovanoviclois arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT mccancedavidr arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT ivanisevicmarina arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT durangarciasantiago arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT brøndstedlise arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT nazeriavideh arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT dammpeter arandomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT hodmoshe randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT mathiesenelisabethr randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT jovanoviclois randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT mccancedavidr randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT ivanisevicmarina randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT durangarciasantiago randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT brøndstedlise randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT nazeriavideh randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes
AT dammpeter randomizedtrialcomparingperinataloutcomesusinginsulindetemirorneutralprotaminehagedornintype1diabetes